Shire to present ADHD portfolio data

At the annual meeting of the American Psychiatric Association to be held next week in San Diego, Shire has announced it is to present the scientific data relating to its Attention-Deficit/Hyperactivity Disorder (ADHD) product portfolio.

The firm’s treatments in this field include long-acting stimulant Adderall XR (mixed salts of a single-entity amphetamine product), ADHD patch Daytrana (methylphenidate transdermal system) and a prodrug stimulant due to launch this quarter, Vyvanse (lisdexamfetamine dimesylate).

Adderall XR is indicated for use in adolescents, while Vyvanse is recommended for use in children aged six to 12.

Other ADHD treatments currently in development by the company include the SPD503 (guanfacine HCl extended release) and SPD465 (triple-bead mixed amphetamine salts) drug candidates.

Eliseo Salinas, chief scientific officer and executive vice-president of global research and development at the firm, said: “The upcoming clinical research to be presented at APA reaffirms Shire’s commitment to understanding the science of ADHD treatment.”

He added that Shire was anticipating sharing the scientific data from its clinical trials relating to its ADHD treatments with others in the medical community.

In February 2007, Shire announced that its planned $2.6 billion (1.33 billion pound) acquisition of New River Pharmaceuticals would enable it to realise the full economic value of Vyvanse.